PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population; Phase 1b data demonstrate ...

Palisade Bio (NASDAQ:PALI) said it generated encouraging safety, pharmacokinetic and early efficacy signals from an open-label Phase 1b study of PALI-2108 in fibrostenotic Crohn’s disease, a difficult ...

Nitrogen is often the most limiting factor when it comes to crop productivity. A recent three-year study concluded that Pivot Bio’s microbial products effectively deliver nitrogen while delivering ...

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the penny stocks with the potential to rise 1000 percent. Gossamer Bio remained in ...

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute ...

The study's main contributors include (L-R) graduate student Joshua Shaffer, professor Upasna Sharma, and postdoc Alka Gupta. (Photo by Carolyn Lagattuta) The pioneering research of UC Santa Cruz’s ...

The lack of a dose-response effect could be due to the high number of dropouts in the higher-dose Winrevair arm and the relatively small study population, a discussant for Merck explained.

The last time I spoke about Upstream Bio, Inc. (UPB) it was in a Seeking Alpha article entitled "Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation." With respect to this ...

New research is significantly revising a widely cited evolutionary model, the Inhibitory Cascade Mode (ICM). Benjamin Auerbach, professor in the Department of Ecology and Evolutionary Biology at the ...